Copeptin, insulin resistance, and risk of incident diabetes in older men

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3332-3339

  Wannamethee, S Goya ^a   Welsh, Paul ^b   Papacosta, Olia ^a   Lennon, Lucy ^a   Whincup, Peter H ^c   Sattar, Naveed ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COPEPTIN; GLUCOSE; INSULIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR; GLYCOPEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; WAIST CIRCUMFERENCE; BLOOD; DIABETES MELLITUS, TYPE 2; INCIDENCE; MIDDLE AGED; PHYSIOLOGY; PREVALENCE; RISK;

AGED; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; GLYCOPEPTIDES; GREAT BRITAIN; HUMANS; INCIDENCE; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RISK;

EID: 84941712330     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/JC.2015-2362     Document Type: Article

References (40)

1. Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92:3973-3978.
2. Barrett LK, SingerM,Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med. 2007;35:33-40.
3. Oshikawa S, Tanoue A, Koshimizu TA, Kitagawa Y, Tsujimoto G. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol. 2004;65:623-629.
4. Spruce BA, McCulloch AJ, Burd J, et al. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf). 1985;22:463-468.
5. Hiroyama M, Fujiwara Y, Nakamura K, et al. Altered lipid metabolism in vasopressin V1B receptor-deficient mice. Eur J Pharmacol. 2009;602:455-461.
6. Kchler S, Perwitz N, Schick RR, Klein J, Westphal S. Argininevasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes. Regul Pept. 2010; 164:126-132.
7. Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron. 2001;87:8-18.
8. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112-119.
9. Saleem U, Khaleghi M, Morgenthaler NG, et al., Kullo IJ. Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab. 2009;94:2558-2564.
10. Enhörning S, Struck J, Wirfält E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E1065-E1072.
11. Enhörning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond). 2013;37:598-603.
12. Asferg CL, Andersen UB, Linneberg A, Goetze JP, Jeppesen JL. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men. Diabet Med. 2014;31:728-732.
13. Then C, Kowall B, Lechner A, et al. Plasma copeptin is associated with type 2 diabetes in men but not in women in the populationbased KORA F4 Study. Acta Diabetol. 2015;103-12.
14. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102-2108.
15. Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) Study. Diabetologia. 2012;55:1963-1970.
16. Salomaa V, Havulinna A, Saarela O, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010;5:e10100.
17. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older nondiabetic men. Atherosclerosis. 2005;181:101-108.
18. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care. 2008;31: 995-1000.
19. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA. 2004;291: 1978-1986.
20. Shaper AG, Pocock SJ, Walker M, Cohen NM, Wale CJ. British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. BMJ. 1981;283:179-186.
21. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002;105:1785-1790.
22. Wannamethee SG, Shaper AG, Whincup PH, Lennon L. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005;28:2913-2918.
23. Wannamethee SG, Welsh P, Whincup PH, Lennon L, Papacosta O, Sattar N. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study. Eur J Heart Fail. 2014;16:25-32.
24. Emberson J, Whincup PH, Walker M, Thomas M, Alberti KG. Biochemical measures in a population-based study: effect of fasting duration and time of day. Ann Clin Biochem. 2002;39:493-501.
25. Trinder P. Determination of blood glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem. 1969;6:24-27.
26. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993;39:578-582.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
29. Walker M, Shaper AG, Lennon L, Whincup PH. Twenty year follow-up of a cohort study based in general practices in 24 British towns. J Publ Health Med. 2000;22:479-485.
30. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2002;51:1131-1137.
31. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail. 2010;16(suppl 1):S37-S44.
32. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 2003;18:892-898.
33. Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol. 2013; 167:1750-1759.
34. Kataan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly. 2010;140: w13101.
35. Veldhuis JD, Sharma A, Roelfsema F. Age-dependent and genderdependent regulation of hypothalamic-adrenocorticotropic-adrenal axis. Endocrinol Metab Clin North Am. 2013;42:201-225.
36. Cowen LE, Hodak SP, Verbalis JG. Age-associated abnormalities of water homeostasis. Endocrinol Metab Clin North Am. 2013;42: 349-370.
37. Roussel R, Fezeu L, Bouby N, et al. Low water intake and risk for new-onset hyperglycemia. Diabetes Care. 2011;34:2551-2554.
38. Pfister R, Sharp S, Luben R, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8:e1001112.
39. Wannamethee SG, Whincup PH, Thomas MC, Sattar N. Associations between dietary fiber and inflammation, hepatic function, and risk of type 2 diabetes in older men: potential mechanisms for the benefits of fiber on diabetes risk. Diabetes Care. 2009;32:1823-1825.
40. Reutrakul S, Van Cauter E. Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. Ann NY Acad Sci. 2014;1311:151-173.